학술논문
Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)
Document Type
Abstract
Author
Source
In Blood 16 November 2008 112(11):2586-2586
Subject
Language
ISSN
0006-4971